OpenAI Acquires Orchestra Bio to Push AI Deeper Into Drug Development
OpenAI is acquiring life sciences startup Orchestra Bio, folding its team and technology into Rosalind, the company's AI model for life sciences research, and the related Rosalind Workbench tool. The Workbench is designed as a harness that helps researchers plan experiments and interpret results rather than simply answer questions. The deal marks OpenAI's most explicit move yet from general-purpose models into vertical scientific workflows.
Orchestra Bio's team and technology will be absorbed into OpenAI's Rosalind life sciences effort
Rosalind Workbench is positioned as an experiment-planning and results-analysis harness for researchers
The acquisition targets biopharma R&D acceleration rather than consumer health applications